Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

and Scope This guidance provides a data-supported approach to the diagnosis, staging, and treatment of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is different from a guideline. Guidelines are developed by a multidisciplinary panel of experts who rate the quality (level) of the evidence and the strength of each recommendation using the Grading of Recommendations Assessment, Development, and Evaluation system (GRADE). A guidance document is developed by a panel of experts in the topic, and guidance statements, not recommendations, are put forward to help clinicians understand and implement the most recent evidence. which The focused and treatment of HCC. However, some areas of HCC lacked sufficient data to perform systematic reviews, and here the authors will the 2010 American Association the Study of Diseases Guidelines, hereto referred as the guidance for HCC. biopsy has a risk of bleeding, tumor seeding, and the pos-sibility that a negative biopsy is attributed to the failure to obtain tissue representative of the nodule rather than a truly benign nodule. first-line of subjects carcinoma